Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.

about

Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.

Item

http://www.wikidata.org/entity/Q46898020

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@en

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@nl

type

Item

label

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@en

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@nl

prefLabel

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@en

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@nl

P1476

Association of Primary Tumor S ...... Metastatic Colorectal Cancer.

@en

P2093

Brice Jabo

http://www.w3.org/2001/XMLSchema#string

Carlos Garberoglio

http://www.w3.org/2001/XMLSchema#string

John W Morgan

http://www.w3.org/2001/XMLSchema#string

Khaled Bahjri

http://www.w3.org/2001/XMLSchema#string

Laurel A Guthrie

http://www.w3.org/2001/XMLSchema#string

Maheswari Senthil

http://www.w3.org/2001/XMLSchema#string

Majed Ramadan

http://www.w3.org/2001/XMLSchema#string

Mark E Reeves

http://www.w3.org/2001/XMLSchema#string

Matthew Selleck

http://www.w3.org/2001/XMLSchema#string

Mayada A Aljehani

http://www.w3.org/2001/XMLSchema#string

P2860

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.

Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data.

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.

Is there a difference in survival between right- versus left-sided colon cancers?

VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival.

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Are there two sides to colorectal cancer?

Recommendations for presenting analyses of effect modification and interaction.

P31

scholarly article

P356

10.1001/JAMASURG.2017.3466

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975237

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

bevacizumab

cetuximab

P932

5833618

http://www.w3.org/2001/XMLSchema#string